X. Palomer

Type de document

Articles (10) Recensions (3)

Co-auteur

Date

Source

Mot-clé

protéine (7) Treatment (7) Mice (7) Protein kinases (6) Inflammation (6) Glucose (6) Animals (6) effet (5) Liver (5) Insulin resistance (5) Growth (5) Growth (5) stress (4) maladie (4) différenciation (4) Differentiation (4) Patients (4) Non-insulin-dependent diabetes (4) Human beings (4) Liver cells (4) Use (4) Patients (4) maladie (4) thérapie (3) spectacle (3) ligne (3) Development (3) Control (3) Transduction (3) Transcription (3)

Documents écrit par X. Palomer (10) | parle de X. Palomer (0)

GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway.
E. Barroso et al.
Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ.
M. Zhang et al.
Striking a gut-liver balance for the antidiabetic effects of metformin.
E. Barroso et al.
A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects.
E. Barroso et al.
Knocking on GDF15's door for the treatment of type 2 diabetes mellitus.
E. Barroso et al.
GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK.
E. Barroso et al. (10 août 2021)
The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance.
X. Palomer et al. (9 août 2021)
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
M. Zarei et al.
Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.
I. El Kochairi et al. (2011)
Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.
L. Serrano et al. (2008)